DGAP-News

Sangui BioTech International Inc.: Revenues slightly improved in the first half of the 2015 financial year

DGAP-News: Sangui BioTech International Inc. / Key word(s): Quarter
Results
Sangui BioTech International Inc.: Revenues slightly improved in the
first half of the 2015 financial year

12.02.2015 / 12:00

---------------------------------------------------------------------

Sangui BioTech: Revenues slightly improved in the first half of the 2015
financial year

Research and development focuses on preclinical trials

Witten, Germany, February 12, 2015

For the first half (as of December 31, 2014) of its 2015 financial year
Sangui BioTech International, Inc. reports revenues from product sales and
royalties in the amount of USD104,906 an increase of 74.0% over the
revenues in the first half of the financial year 2014. In the second
quarter (October through December 2014) revenues amounted to USD31,166 a
decrease of 57.7% as compared with the most recent quarter(July through
September 2014).

Research and development expenses amounted to USD134,977 (H1/2014: USD
107,234). The increase is due to the ongoing preclinical trials aimed at
demonstrating the functionality of Sangui's technology with respect to
various indications. The net loss attributable to shareholders of the
parent company came to USD355,928 (H1/2014: USD570,032), the cash outflow
from operations during the six months amounted to USD318,740 (H1/2014:
USD337,419).

As of December 31, 2014, the equity ratio was minus 33.3% (June 30, 2014:
2.8%).

In the course of the second quarter, preclinical trials at Giessen
University demonstrated that a hemoglobin based product developed by
SanguiBioTech is apt to improve the oxygen supply of vital organs. It is
now being supposed that Sangui's hemoglobin-based artificial oxygen
carriers may interrupt the self-perpetuating mechanism of septic shock,
that has so far been highly resistant to treatment, and may thus ultimately
reduce the high mortality rates.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares
of which are being traded on the OTCQB marketplace (www.otcmarkets.com:
SGBI) and the OTC markets of Berlin and Hamburg-Hannover stock exchanges.
Its purpose is to provide financing and access to the capital markets for
the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.

For more information please contact:

Joachim Fleing
Phone: [phone]
Fax: [phone]
e-mail: [e-mail]

Some of the statements contained in this news release discuss future
expectations, contain projections of results of operation or financial
condition or state other "forward-looking" information. These statements
are subject to known and unknown risks, uncertainties, and other factors
that could cause the actual results to differ materially from those
contemplated by the statements. The forward-looking information is based on
various factors and is derived using numerous assumptions. Important
factors that may cause actual results to differ from projections include,
among many others, the ability of the Company to raise sufficient capital
to meet operating requirements. Words such as "anticipates," "expects,"
"intends," "plans," "believes," "seeks," "estimates," and variations of
such words and similar expressions are intended to identify such
forward-looking statements. Unless required by law, the Company undertakes
no obligation to update publicly any forward-looking statements, whether as
a result of new information, future events or otherwise.



---------------------------------------------------------------------

12.02.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


322423 12.02.2015